View Older Stories

May 14, 2026 04:59PM Evercore ISI Reinstates Biogen (BIIB) at Outperform

May 14, 2026 12:04PM Biogen (BIIB) PT Raised to $300 at Oppenheimer

May 14, 2026 08:35AM Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'

May 14, 2026 08:17AM Mizuho Reiterates Outperform Rating on Biogen (BIIB)

May 14, 2026 07:44AM Wolfe Research on Biogen (BIIB): 'Re-mem-BIIB-er This Day, BIIB Is Moving Tau Forward'

May 14, 2026 07:29AM Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'

May 14, 2026 07:16AM Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s

May 7, 2026 05:19PM Bright Horizons Family Solutions and Remitly Global to Join S&P SmallCap 600

May 1, 2026 01:05PM Freedom Broker Upgrades Biogen (BIIB) to Buy, raises PT to $245

May 1, 2026 06:52AM H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)

Apr 30, 2026 04:00PM Biogen (BIIB) PT Raised to $190 at Truist Securities

Apr 30, 2026 08:28AM Biogen (BIIB) PT Raised to $222 at RBC Capital

Apr 30, 2026 08:26AM Biogen (BIIB) PT Raised to $196 at Wedbush

Apr 30, 2026 07:35AM Biogen (BIIB) PT Lowered to $200 at Bernstein SocGen Group

Apr 30, 2026 07:12AM Biogen (BIIB) PT Raised to $260 at Guggenheim

Apr 29, 2026 02:58PM Biogen (BIIB) PT Raised to $203 at BofA Securities

Apr 29, 2026 06:18AM Biogen (BIIB) Tops Q1 EPS by 62c; cuts EPS guidance

Apr 27, 2026 09:45AM Truist Securities Reiterates Hold Rating on Biogen (BIIB)

Apr 26, 2026 08:00PM U.S. Biotech stocks: Q1 earnings previews

Apr 24, 2026 03:38PM Biogen (BIIB) PT Raised to $200 at BofA Securities

Apr 22, 2026 09:53AM UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts

Apr 22, 2026 02:46AM UBS Upgrades Biogen (BIIB) to Buy

Apr 20, 2026 07:31AM Biogen acquires TJ Biopharma's felzartamab rights in China for $850M

Apr 13, 2026 05:05PM Piper Sandler Upgrades Biogen (BIIB) to Overweight

Apr 6, 2026 06:36AM Biogen expects $34 million charge in first quarter 2026

Apr 2, 2026 06:43AM Biogen (BIIB) PT Raised to $237 at H.C. Wainwright

Apr 1, 2026 07:11AM Biogen (BIIB) PT Raised to $245 at Canaccord

Mar 31, 2026 03:28PM William Blair on Biogen (BIIB): 'we see potential to add $1.54 billion in sales' through APLS deal

Mar 31, 2026 01:28PM Guggenheim Reiterates Buy Rating on Biogen (BIIB) following Apellis deal

Mar 31, 2026 11:55AM William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform

Mar 31, 2026 10:15AM Biogen (BIIB) call put ratio 1.6 calls to 1 put after acquiring Apellis (APLS)

Mar 31, 2026 09:47AM Barclays on Biogen (BIIB): Apellis deal 'signals confidence' ahead of felzartamab readouts

Mar 31, 2026 09:42AM Stifel on Biogen (BIIB): Apellis acquisition 'surprising,' but makes sense given move towards rare kidney

Mar 31, 2026 09:36AM BMO Capital on Biogen (BIIB): Apellis deal 'sets a clear path for further expansion in nephrology'

Mar 31, 2026 06:50AM Biogen to acquire Apellis Pharmaceuticals for $5.6 billion or $41/sh plus CVR

Mar 30, 2026 04:41PM BofA Securities on Biogen (BIIB): 'clear positive trend in execution'

Mar 30, 2026 10:37AM Biogen will introduce 28 mg vial at same price as 12 mg vial, resulting in parity pricing for patients in the maintenance phase - Spokesperson

Mar 30, 2026 09:31AM BMO Capital Reiterates Market Perform Rating on Biogen (BIIB)

Mar 30, 2026 09:25AM Morgan Stanley Reiterates Equalweight Rating on Biogen (BIIB)

Mar 30, 2026 09:24AM Jefferies Reiterates Buy Rating on Biogen (BIIB) following FDA approval of HD Spinraza for SMA

Mar 20, 2026 12:13PM LEQEMBI shows high treatment persistence in real-world study

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 11, 2026 04:54PM Oppenheimer Reiterates Outperform Rating on Biogen (BIIB): "continue to view SMA as an important franchise"

Mar 11, 2026 08:00AM Biogen reports positive salanersen trial results in SMA patients

Feb 20, 2026 06:02AM Barclays Starts Biogen (BIIB) at Equalweight

Feb 11, 2026 05:00PM Biogen names Dr. Maria Freire as new board chair

Feb 9, 2026 09:46AM Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)

Feb 9, 2026 09:39AM Biogen (BIIB) PT Raised to $196 at BMO Capital

Feb 9, 2026 09:25AM Biogen (BIIB) PT Raised to $215 at TD Cowen

Feb 9, 2026 09:08AM Biogen (BIIB) PT Raised to $233 at RBC Capital

View Older Stories